These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 30405034)

  • 1. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
    Yen CH; Hsiao HH
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.
    Manni S; Carrino M; Semenzato G; Piazza F
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
    Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
    Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.
    Riz I; Hawley TS; Marsal JW; Hawley RG
    Oncotarget; 2016 Oct; 7(41):66360-66385. PubMed ID: 27626179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow myeloid cells in regulation of multiple myeloma progression.
    Herlihy SE; Lin C; Nefedova Y
    Cancer Immunol Immunother; 2017 Aug; 66(8):1007-1014. PubMed ID: 28378067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.
    Yen CH; Hsu CM; Hsiao SY; Hsiao HH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
    Ria R; Vacca A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
    Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
    Yang WC; Lin SF
    Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
    Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
    Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
    Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
    Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
    Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma.
    Al-Odat OS; Guirguis DA; Schmalbach NK; Yao G; Budak-Alpdogan T; Jonnalagadda SC; Pandey MK
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
    Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH
    Blood; 2017 Apr; 129(14):1969-1979. PubMed ID: 28151428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation.
    Wang X; Li C; Ju S; Wang Y; Wang H; Zhong R
    Leuk Lymphoma; 2011 Oct; 52(10):1991-8. PubMed ID: 21718132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
    Shay G; Hazlehurst L; Lynch CC
    J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment.
    Tang W; Xu J; Xu C
    Cancer Lett; 2023 Mar; 556():216081. PubMed ID: 36739065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adhesion molecules--The lifelines of multiple myeloma cells.
    Katz BZ
    Semin Cancer Biol; 2010 Jun; 20(3):186-95. PubMed ID: 20416379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microenvironment drug resistance in multiple myeloma: emerging new players.
    Di Marzo L; Desantis V; Solimando AG; Ruggieri S; Annese T; Nico B; Fumarulo R; Vacca A; Frassanito MA
    Oncotarget; 2016 Sep; 7(37):60698-60711. PubMed ID: 27474171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
    Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
    Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.